These traditional approaches are expensive and time consuming. Our approach eliminates the need for whole animals or perfused organs in early drug development and metabolic screening. Our ultrafiltration mass spectrometry methods are also faster and promise to be much less expensive. A provisional patent application was filed. The technology has been applied to the measurement of serum albumin binding and screening drug candidates for metabolism.
More work is in progress.
If you want to expedite the receipt of this information, please fax a signed copy of the CDA to the contact. If you wish to modify the CDA, please discuss it with the contact.